KO Client Whitecap Biosciences Acquired by Bausch + Lomb

KO client Whitecap Biosciences, which is developing two innovative therapies for potential use in glaucoma and geographic atrophy, was recently acquired by Bausch + Lomb, a leading global eye health company to strengthen its expanding clinical stage pipeline.

“Glaucoma and geographic atrophy can cause severe vision loss, with many patients experiencing progressive deterioration,” said Scott Whitcup, MD, a founder and former CEO of Whitecap Biosciences in a press release from Bausch + Lomb. “By joining a global leader like Bausch + Lomb, we hope Whitecap’s assets will be developed into effective treatments that improve visual outcomes for patients.”

KO partner Brad Schoenfeld, partner Kevin Gibson, attorney Nadia Bryan, and paralegal Sara Richissin represented Whitecap Biosciences in the acquisition. Learn more on CNBC and in the Opthalmology Times.